Table 4.
Immunohistochemical characteristics of basal cell neoplasms and adenoid cystic carcinomas
| BCACs (n=7) | BCAs with ci. (n=10) | BCAs without ci. (n=10) | ACCs (n=10) | |
|---|---|---|---|---|
| Cytokeratin 5/6* |
7 (100%) |
9 (90%) |
10 (100%) |
3 (30%) |
| S100P protein |
0 (0%) |
1 (10%) |
1 (10%) |
5 (50%) |
| β-catenin** |
7 (100%) |
7 (70%) |
10 (100%) |
0 (0%) |
| CD117 |
4 (57%) |
6 (60%) |
10 (100%) |
10 (100%) |
| EGFR |
3 (43%) |
2 (20%) |
9 (90%) |
5 (50%) |
| p53 |
0 (0%) |
1 (10%) |
2 (20%) |
6 (60%) |
| Ki-67$ | 0 (0%) | 2 (20%) | 2 (20%) | 10 (100%) |
*diffuse staining only; **nuclear staining only; $Ki-67 labeling index > 5%
ACC, adenoid cystic carcinoma; BCAC, basal cell adenocarcinoma; BCA, basal cell adenoma; ci., capsular invasion; EGFR, epidermal growth factor receptor.